SG11201408536WA - METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF - Google Patents
METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOFInfo
- Publication number
- SG11201408536WA SG11201408536WA SG11201408536WA SG11201408536WA SG11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- penzberg
- pct
- fusion
- denotes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2014/020056 A1 6 February 2014 (06.02.2014) WIPO I PCT (51) International Patent Classification: C12N15/79 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/066065 31 July 2013 (31.07.2013) English English (30) Priority Data: 12179025.7 2 August 2012 (02.08.2012) (71) Applicant (for all designated States except US): F. HOFF MANN-LA ROCHE AG [CH/CH]; Grenzacher Strasse 124, CH-4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. I |i (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors: RUEGER, Petra; Auf der Leiten 4, 82377 Penzberg (DE). SCHLOTHAUER, Tilman; Sommer- strasse 3a, 82377 Penzberg (DE). SEEBER, Stefan; Bre- unetsrieder Weg 22, 82377 Penzberg (DE). (74) Agents: SKOLAUT, Alexander et al.; Roche Diagnostics GmbH, Patent Department (LPP 6164), P.O.Box 11 52, 82372 Penzberg (DE). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V© © o CJ o o CJ o & (54) Title: METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF (57) Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes heavy chain Fc-region polypeptide, wherein a R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12179025 | 2012-08-02 | ||
PCT/EP2013/066065 WO2014020056A1 (en) | 2012-08-02 | 2013-07-31 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408536WA true SG11201408536WA (en) | 2015-01-29 |
Family
ID=48986096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408536WA SG11201408536WA (en) | 2012-08-02 | 2013-07-31 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
Country Status (17)
Country | Link |
---|---|
US (2) | US10011644B2 (en) |
EP (1) | EP2880170B1 (en) |
JP (1) | JP6307077B2 (en) |
KR (1) | KR20150038511A (en) |
CN (1) | CN104508132B (en) |
BR (1) | BR112015002263A2 (en) |
CA (1) | CA2876096A1 (en) |
DK (1) | DK2880170T3 (en) |
ES (1) | ES2602030T3 (en) |
HK (1) | HK1208881A1 (en) |
HU (1) | HUE029634T2 (en) |
MX (1) | MX2015000681A (en) |
PL (1) | PL2880170T3 (en) |
RU (1) | RU2630659C2 (en) |
SG (1) | SG11201408536WA (en) |
SI (1) | SI2880170T1 (en) |
WO (1) | WO2014020056A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2726092T3 (en) | 2011-06-28 | 2019-11-29 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
RU2746550C2 (en) * | 2014-10-27 | 2021-04-15 | Инхибркс, Инк. | Fused serpine polypeptides and methods of their application |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
RU2746486C2 (en) * | 2015-03-13 | 2021-04-14 | Юниверсити Оф Мэрилэнд, Балтимор | Universal antibody-mediated biosensor |
EP3356829A4 (en) * | 2015-10-02 | 2019-02-27 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Binding assays and method for probing antibody function with fc binding multimers |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
CN109311949B (en) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | Method for storing separation matrices |
ES2909833T3 (en) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Cleaning and/or disinfection method of a separation matrix |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
ES2874974T3 (en) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Separation matrix |
SG11201810697QA (en) * | 2016-06-07 | 2018-12-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
CN112585165A (en) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | Optimized anti-TL 1A antibodies |
JP2022512629A (en) * | 2018-10-23 | 2022-02-07 | マジェンタ セラピューティクス インコーポレイテッド | Fc silenced antibody drug conjugate (ADC) and its use |
BR112021007175A2 (en) | 2018-10-23 | 2021-08-10 | Dragonfly Therapeutics, Inc. | proteins fused to heterodimeric FC |
CN114901311A (en) | 2019-10-24 | 2022-08-12 | 普罗米修斯生物科学公司 | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
SK9432001A3 (en) * | 1999-01-07 | 2003-02-04 | Lexigen Pharm Corp | Expression and export of anti-obesity proteins as Fc fusion proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1200124B1 (en) * | 1999-07-13 | 2008-09-10 | Bolder Biotechnology, Inc. | Erythropoietin-immunoglobulin fusion proteins |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
DE60332957D1 (en) | 2002-12-16 | 2010-07-22 | Genentech Inc | IMMUNOGLOBULIN VARIANTS AND ITS USES |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
CN101124245A (en) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CA2676098A1 (en) | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble fcgammaria and related methods |
US8658766B2 (en) | 2008-06-27 | 2014-02-25 | Zymogenetics, Inc. | Soluble hybrid Fcγ receptors and related methods |
EP2365979A2 (en) | 2008-10-22 | 2011-09-21 | Biogen Idec MA Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
AR080794A1 (en) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
-
2013
- 2013-07-31 BR BR112015002263A patent/BR112015002263A2/en not_active IP Right Cessation
- 2013-07-31 RU RU2015104625A patent/RU2630659C2/en not_active IP Right Cessation
- 2013-07-31 PL PL13750004T patent/PL2880170T3/en unknown
- 2013-07-31 JP JP2015524773A patent/JP6307077B2/en active Active
- 2013-07-31 ES ES13750004.7T patent/ES2602030T3/en active Active
- 2013-07-31 DK DK13750004.7T patent/DK2880170T3/en active
- 2013-07-31 CA CA2876096A patent/CA2876096A1/en not_active Abandoned
- 2013-07-31 HU HUE13750004A patent/HUE029634T2/en unknown
- 2013-07-31 SG SG11201408536WA patent/SG11201408536WA/en unknown
- 2013-07-31 SI SI201330354A patent/SI2880170T1/en unknown
- 2013-07-31 EP EP13750004.7A patent/EP2880170B1/en active Active
- 2013-07-31 CN CN201380040154.7A patent/CN104508132B/en active Active
- 2013-07-31 WO PCT/EP2013/066065 patent/WO2014020056A1/en active Application Filing
- 2013-07-31 KR KR20157005311A patent/KR20150038511A/en not_active Application Discontinuation
- 2013-07-31 MX MX2015000681A patent/MX2015000681A/en unknown
-
2015
- 2015-02-02 US US14/611,645 patent/US10011644B2/en active Active
- 2015-09-29 HK HK15109569.5A patent/HK1208881A1/en unknown
-
2018
- 2018-06-04 US US15/996,846 patent/US10093714B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104508132A (en) | 2015-04-08 |
HUE029634T2 (en) | 2017-03-28 |
PL2880170T3 (en) | 2017-02-28 |
DK2880170T3 (en) | 2016-10-24 |
JP6307077B2 (en) | 2018-04-04 |
US10011644B2 (en) | 2018-07-03 |
SI2880170T1 (en) | 2016-12-30 |
EP2880170B1 (en) | 2016-08-24 |
RU2630659C2 (en) | 2017-09-11 |
US20150140683A1 (en) | 2015-05-21 |
US20180265564A1 (en) | 2018-09-20 |
ES2602030T3 (en) | 2017-02-17 |
CN104508132B (en) | 2017-09-15 |
CA2876096A1 (en) | 2014-02-06 |
JP2015526429A (en) | 2015-09-10 |
EP2880170A1 (en) | 2015-06-10 |
MX2015000681A (en) | 2015-04-10 |
HK1208881A1 (en) | 2016-03-18 |
BR112015002263A2 (en) | 2017-12-12 |
RU2015104625A (en) | 2016-09-20 |
US10093714B1 (en) | 2018-10-09 |
WO2014020056A1 (en) | 2014-02-06 |
KR20150038511A (en) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
SG11201807426WA (en) | Immunomodulators | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201408261UA (en) | Syringe | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
SG11201407233RA (en) | Ethylene oligomerization process | |
SG11201407774XA (en) | Conversion of biomass | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201808476SA (en) | Recycling of polymer matrix composite | |
SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same |